NervGen Pharma (9UA) Stock Statistics & Valuation Metrics
Total Valuation
NervGen Pharma has a market cap or net worth of EUR 132.01M. The enterprise value is EUR 155.34M.
- Market Cap
- EUR 132.01M
- Enterprise Value
- EUR 155.34M
Share Statistics
NervGen Pharma has 107,616,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 107,616,410
- Owned by Insiders
- 15.64%
- Owned by Institutions
- 0.27%
Financial Efficiency
NervGen Pharma’s return on equity (ROE) is -12.69 and return on invested capital (ROIC) is -719.57%.
- Return on Equity (ROE)
- -12.69
- Return on Assets (ROA)
- -1.90
- Return on Invested Capital (ROIC)
- -719.57%
- Return on Capital Employed (ROCE)
- -7.21
- Revenue Per Employee
- 0
- Profits Per Employee
- -5.51M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NervGen Pharma is -2.23. NervGen Pharma’s PEG ratio is 0.02.
- PE Ratio
- -2.23
- PS Ratio
- 0.00
- PB Ratio
- 10.09
- Price to FCF
- -6.86
- Price to Operating Cash Flow
- -5.90
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, NervGen Pharma had revenue of 0 and earned -44.12M in profits. Earnings per share was -0.61.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -25.08M
- Pretax Income
- -44.12M
- Net Income
- -44.12M
- EBITDA
- -5.65M
- Earnings Per Share (EPS)
- -0.61
Cash Flow
In the last 12 months, operating cash flow was -29.60M and capital expenditures 4, giving a free cash flow of -29.60M billion.
- Operating Cash Flow
- -29.60M
- Free Cash Flow
- -29.60M
- Free Cash Flow per Share
- -0.32
Dividends & Yields
NervGen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.57%
- Earnings Yield
- -38.69%
Stock Price Statistics
- Beta
- 0.48
- 52-Week Price Change
- -45.50%
- 50-Day Moving Average
- 1.63
- 200-Day Moving Average
- 2.36
- Relative Strength Index (RSI)
- 31.70
- Average Volume (3m)
- 3,110
Important Dates
NervGen Pharma upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
NervGen Pharma as a current ratio of 1.16, with Debt / Equity ratio of 0.24%
- Current Ratio
- 1.16
- Quick Ratio
- 1.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.90
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, NervGen Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NervGen Pharma EV to EBITDA ratio is -10.01, with an EV/FCF ratio of -3.93.
- EV to Sales
- 0.00
- EV to EBITDA
- -10.01
- EV to Free Cash Flow
- -3.93
- EV to Operating Cash Flow
- -3.93
Balance Sheet
NervGen Pharma has EUR 86.93M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 86.93M billion.
- Cash & Marketable Securities
- EUR 86.93M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 86.93M
- Net Cash Per Share
- EUR 0.81
- Tangible Book Value Per Share
- EUR 0.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for NervGen Pharma is EUR 8.95, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 8.95
- Price Target Upside
- 640.00% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 23.26%
Scores
- Smart Score
- 1
- AI Score
- ―
